世界の骨粗しょう症治療・予防市場予測:抗嘔吐薬、骨粗しょう症治療薬、再吸収阻害薬、同化薬...市場調査レポートについてご紹介

【英文タイトル】Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Executive Summary
1.1 The Global Osteoporosis Drug Market Review
1.2 The Global Osteoporosis Drug Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Osteoporosis
2.1 Osteoporosis Prevalence and Incidence, 2014
2.2 Osteoporosis: The Silent Killer
2.3 Osteoblasts are Critical in Bone Healing
2.4 Classifying Osteoporosis by Types
2.5 Classifying Osteoporosis by Treatments
2.5.1 Antiresorptive Medication
2.5.2 Anabolic Medication
2.6 Osteoporosis Risk Factors

3. The Global Osteoporosis Drug Market, 2014-2024
3.1 Scope of this Report
3.2 The Global Osteoporosis Drug Market in 2013
3.3 The Global Osteoporosis Drug Market: Sales Forecast 2014-2024
3.4 Breakdown of the World Osteoporosis Drug Market by Therapeutic Classes, 2013
3.5 The Global Osteoporosis Drug Market by Therapeutic Classes: Sales Forecast 2014-2024
3.6 Breakdown of the World Osteoporosis Drug Market by Leading Drugs, 2013
3.6.1 The Global Osteoporosis Drug Market by Leading Drugs: Sales Forecast 2014-2024
3.7 Which Osteoporosis Drugs Will Lead the Market in 2024?
3.7.1 Osteoporosis Products Pipeline, 2014
3.7.2 Forteo (Teriparatide) -Eli Lilly, 2014
3.7.3 Evista(Raloxifene) – Eli Lilly, 2014
3.7.4 Prolia (Denosumab) – Amgen, GSK and Daiichi Sankyo, 2014
3.7.5 Actonel/Atelvia (Risendronate) -Sanofi, Actavis, Ajinomoto Pharmaceuticals and Eisai, 2014
3.7.6 Fosamax (Alendronate) – Merck, 2014
3.7.7 Reclast/Aclasta (Zoledronic Acid) – Novartis, 2014
3.7.8 Boniva (Ibandronate) –Roche and GSK, 2014
3.7.9 Duavee (Bazedoxifene/Conjugated Estrogens) – Pfizer and Ligand Pharmaceuticals, 2014
3.7.10 Odanacatib (MK 0822) – Merck, 2014
3.7.11 Romosozumab (AMG 785) – Amgen and UCB, 2014
3.7.12 The Global Osteoporosis Drug Market: Drivers and Restraints 2014-2024

4. Leading National Osteoporosis Drug Markets, 2014-2024
4.1 Regional Breakdown of the World Osteoporosis Drug Market, 2013
4.2 Regional Breakdown of the World Osteoporosis Drug Market: Sales Forecast by Region, 2014-2024
4.3 How Will Regional Market Shares Change to 2024?
4.4 The US Osteoporosis Drug Market, 2013
4.4.1 The US Osteoporosis Drug Market: Forecast 2014-2024
4.5 Reimbursement Situation in the US, 2014
4.5.1 The US Keeps Dominating the Osteoporosis Drug Market: What About Healthcare Coverage?
4.6 The US Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
4.7 The Leading European Osteoporosis Drug Markets, 2013
4.7.1 The Leading European Osteoporosis Drug Markets: Forecasts 2014-2024
4.7.2 The German Osteoporosis Drug Market Forecast, 2014-2024
4.7.3 The French Osteoporosis Drug Market Forecast, 2014-2024
4.7.4 The UK Osteoporosis Drug Market Forecast, 2014-2024
4.7.5 The Italian Osteoporosis Drug Market Forecast, 2014-2024
4.7.6 The Spanish Osteoporosis Drug Market Forecast, 2014-2024
4.8 The Japanese Osteoporosis Drug Market, 2013
4.8.1 The Japanese Osteoporosis Drug Market Forecast, 2014-2024
4.8.2 Recent Trends in the Japanese Osteoporosis Drug Market, 2014
4.9 The BRICK Countries Osteoporosis Drug Market, 2013
4.9.1 The BRICK Countries Osteoporosis Drug Market Forecast, 2014-2024
4.9.2 The Chinese Osteoporosis Drug Market Forecast, 2014-2024
4.9.2.1 Main Companies in the Chinese Osteoporosis Drug Market, 2014
4.9.2.2 Growth Drivers in the Chinese Osteoporosis Drug Market, 2014-2024
4.9.3 The Indian Osteoporosis Drug Market Forecast, 2014-2024
4.9.4 The Russian Osteoporosis Drug Market Forecast, 2014-2024
4.9.5 The Brazilian Osteoporosis Drug Market Forecast, 2014-2024
4.9.6 The South Korean Osteoporosis Drug Market Forecast, 2014-2024
4.9.7 The BRICK Countries Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
4.10 The Osteoporosis Drug Market Forecast in the Rest of the World, 2014-2024
4.10.1 Additional Considerations: Challenges for Aging Populations by Region, 2014

5. Global Antiresorptive Drugs Market, 2014-2024
5.1 The Global Antiresorptive Drugs Market Forecast 2014-2024
5.1.1 Breakdown of the Antiresorptive Drugs Market by Drug Category, 2013
5.2 The Global Antiresorptives Drug Market by Drug Category: Sales Forecast 2014-2024
5.3 The Global Bisphosphonates Market, 2013
5.4 The Global Bisphosphonates Drug Market: Sales Forecast 2014-2024
5.5 Breakdown of the Global Bisphosphonates Market: Sales Forecast by Leading Drugs 2014-2024
5.5.1 Actonel/Atelvia (Risedronate)
5.5.1.1 History of Actonel/Atelvia (Risedronate)
5.5.1.2 Generic Competition for Actonel/Atelvia (Risedronate), 2014
5.5.1.3 Actonel/Atelvia (Risedronate) Sales Forecast 2014-2024
5.5.2 Fosamax (Alendronate)
5.5.2.1 History of Fosamax (Alendronate)
5.5.2.2 Generic Competition for Fosamax (Alendronate), 2014
5.5.2.3 Fosamax (Alendronate) Sales Forecast 2014-2024
5.5.3 Reclast/Aclasta (Zoledronic Acid)
5.5.3.1 Reclast/Aclasta (Zoledronic Acid) Strengths and Weaknesses, 2014
5.5.3.2 Reclast/Aclasta (Zoledronic Acid) in the Leading Regional Markets, 2014
5.5.3.3 Generic Competition for Reclast/Aclasta (Zoledronic Acid), 2014
5.5.3.4 Reclast/Aclasta (Zoledronic Acid) Sales Forecast 2014-2024
5.5.4 Boniva (Ibandronate)
5.5.4.1 Boniva (Ibandronate): Sales Forecast 2014-2024
5.6 The Global SERMs Drug Market: Sales Forecast 2014-2024
5.7 Breakdown of the Global SERMs Market: Sales Forecast by Leading Drugs 2014-2024
5.7.1 Evista (Raloxifene)
5.7.1.1 Generic Competition for Evista (Raloxifene), 2014
5.7.1.2 Evista (Raloxifene) Sales Forecast 2014-2024
5.7.2 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens)
5.7.2.1 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens) in the Leading Regional Markets, 2014
5.7.2.2 History of Duavee/Aprela (Bazedoxifene and Conjugated Estrogens)
5.7.2.3 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens) Sales Forecast 2014-2024
5.8 The Global RANKL Antibody Market: Sales Forecast 2014-2024
5.8.1 Prolia (Denosumab)
5.8.1.1 History of Prolia (Denosumab)
5.8.1.2 Prolia to Drive the Market in 2017
5.8.1.3 Safety Profile
5.8.1.4 Prolia: Patent Expiries
5.8.1.5 Prolia (Denosumab) Sales Forecast 2014-2024
5.9 The Global Cathepsin K Inhibitors Market: Sales Forecast 2014-2024
5.9.1 Odanacatib
5.9.1.1 Odanacatib Sales Forecast 2014-2024
5.10 Other Antiresorptive Drugs, 2014
5.10.1 Protelos
5.10.2 Calcitonin-Salmon
5.10.3 Binosto
5.11 Drivers and Restraints for the Global Antiresorptives Drug Market, 2014-2024

6. The Global Anabolic Drugs Market, 2014-2024
6.1 The Global Anabolic Drugs Market, 2013
6.2 The Global Anabolics Drug Market by Drug Category: Sales Forecast 2014-2024
6.3 The Human Recombinant Parathyroid Hormone Peptides Market, 2014
6.3.1 Forteo (Teriparatide) Market: Sales Forecast 2014-2024
6.3.1.1 Forteo Offers a Differentiating Factor in 2014
6.4 The Anti-Sclerostin Market, 2014
6.4.1 Romosozumab: Sales Forecast 2014-2024
6.5 Other Anabolic Drugs
6.5.1 Blosozumab (LY2541546): Second in Class Sclerostin Antibody
6.5.2 ZP-PTH: Parathyroid by Way Micro Needle Patch
6.5.3 ZT-034: Will Need More Than Biomarkers for Approval
6.5.4 Preotact/Preos: Will it be Introduced in the Market Again?
6.5.5 BA-058 (Abaloparatide): Potential Competitor for Forteo
6.5.6 PTH(1-31)NH2: Future Dual-Action Drug

7. Leading Companies in the Osteoporosis Drug Market, 2014
7.1 Leading Companies in the Osteoporosis Drug Market, 2013
7.2 Expected Company Leaders in the OsteoporosisDrug Market in 2024
7.3 Eli Lilly and Co
7.3.1 Eli Lilly Osteoporosis Drug Sales Forecast, 2014-2024
7.4 Amgen
7.4.1 Amgen’s Osteoporosis Product Portfolio
7.4.2 Amgen Osteoporosis Drug Sales Forecast, 2014-2024
7.5 UCB
7.5.1 UCB Osteoporosis Drug Sales Forecast, 2014-2024
7.6 GSK
7.6.1 GSK Osteoporosis Drug Sales Forecast, 2014-2024
7.7 Merck
7.7.1 Merck Osteoporosis Drug Sales Forecast, 2014-2024
7.8 Actavis
7.9 Sanofi
7.10 Pfizer
7.11 Novartis

8. Qualitative Analysis of the Global Osteoporosis Drug Market, 2014-2024
8.1 Pestel Analysis
8.1.1 Political Factors
8.1.2 Economic Factors
8.1.3 Socio-Cultural Factors
8.1.4 Technological Factors
8.1.5 Environmental Factors
8.1.6 Legal Factors
8.2 Porter’s Five Forces Analysis of the Osteoporosis Drugs Market
8.2.1 Competitive Rivalry: High Rivalry Among Competitors
8.2.1.1 Eli Lilly and Amgen Dominate the Biological Osteoporosis Drug Market
8.2.2 Potential Entrants into the Osteoporosis Drug Market: Low Threat of New Entrants
8.2.3 Medium Threat of Substitutes: Who Are The Latent Substitutes?
8.2.4 High Power of Suppliers: Drug Manufacturers Still Have the Power to Lead the Market
8.2.5 High Power of Buyers: Big Pharma to Engulf Smaller Companies
8.3 SWOT Analysis and Strategies
8.3.1 Strengths: Smart Thinking
8.3.2 Weaknesses: Not An Easy Market
8.3.2.1 Patent Expiries
8.3.3 Opportunities: Changing Social Trends
8.3.4 Threats: Highly Stringent but Necessary Regulations
8.3.4.1 Drug Side-Effect Publicity
8.3.4.2 Reimbursement for Bone Metabolism Drugs
8.4 Challenges to Overcome for the Future Osteoporosis Drug Market

9. Expert Opinions
9.1 Interview with Dr. Karl Grindulis, Consultant Rheumatologist at Sandwell General Hospital, West Bromwich, UK
9.1.1 Calcitonin-Salmon in the UK
9.1.2 Personalised Medicine
9.1.3 Expert Views on Romosozumab
9.1.4 Key Factors for the Future
9.2 Interview with Dr. Matthew Drake, Consultant in the Department of Medicine, Division of Endocrinology, Mayo Clinic Rochester, Minnesota, US
9.2.1 Skeletal Anabolic Agents Remain the Biggest Unmet Need
9.2.2 Calcitonin-Salmon: not Recommendable
9.2.3 Shifting to Generics
9.2.4 Romosozumab: Potential Blockbuster
9.2.5 Odanacatib: Intriguing Future Performance
9.2.6 Focusing on Patients with Rare Skeletal Disorders may Give Some Answers

10. Conclusions
10.1 The World Osteoporosis Drug Market by Therapeutic Classes, 2013
10.2 The World Osteoporosis Drug Market Forecast by Drug Category, 2014-2024
10.3 The Global Osteoporosis Drug Market Forecast by Regional Markets, 2014-2024
10.4 The Global Osteoporosis Drug Market Forecast by Leading Drugs, 2014-2024
10.4.1 Leading Companies for the Osteoporosis Drug Market
10.5 Drivers for the Osteoporosis Drugs Market, 2014-2024


【レポート販売概要】

■ タイトル:世界の骨粗しょう症治療・予防市場予測:抗嘔吐薬、骨粗しょう症治療薬、再吸収阻害薬、同化薬
■ 英文:Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies
■ 発行日:2014年5月
■ 調査会社:visiongain
■ 商品コード:VISG409054
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。